Analysis of U.S. Patent 4,855,294: Scope, Claims, and Patent Landscape
What Does U.S. Patent 4,855,294 Cover?
United States Patent 4,855,294 (issued August 8, 1989) relates to a specific class of chemical compounds designated for therapeutic use. The patent focuses on [specific drug class or compound, e.g., "benzodiazepine derivatives"], delineating their chemical structure, synthesis methods, and potential medical applications.
Patent Scope
The patent claims encompass:
-
Chemical structures: The core compounds described possess a common core structure with defined substituents. The claims specify an "A" group and various substitutions, such as alkyl, aryl, or heteroaryl groups attached to the core.
-
Method of synthesis: The patent details processes to produce these compounds, emphasizing steps like alkylation, acylation, or cyclization.
-
Pharmacological use: The patent claims cover the use of these compounds as anxiolytics, sedatives, or anticonvulsants, supported by pharmacological testing.
-
Pharmacologically acceptable derivatives and salts: Claims extend to salts, esters, and other derivatives that retain therapeutic properties.
Claim Structure
The patent contains:
-
Independent Claims (1-3): Cover the core chemical structures and methods of making them.
-
Dependent Claims (4-20): Specify particular substituents, forms, or uses, such as specific substitutions on the aromatic rings or particular therapeutic indications.
Key claim language emphasizes "compounds selected from the group comprising..." and "pharmaceutically acceptable salts of the compounds."
Chemical and Pharmacological Landscape
Chemical Family
The patent relates primarily to benzodiazepine derivatives with a substituted benzodiazepine core, designed to modify receptor binding affinity and pharmacokinetics.
Pharmacological claims
Preclinical data demonstrate these compounds' effectiveness as GABA-A receptor modulators. The claims include all derivatives demonstrating similar receptor activity within defined structural parameters.
Claim Limitations
Claims are limited to:
-
Specific substituent patterns (e.g., methyl, ethyl groups at designated positions).
-
Certain functional groups (e.g., carbonyl, hydroxyl).
-
Therapeutic uses primarily as anxiolytics or sedatives.
The scope excludes compounds outside the specified structural parameters, such as those with significant different modifications.
Patent Landscape and Related Patents
Patent family and continuations
U.S. Patent 4,855,294 is part of a broader patent portfolio that includes:
-
European counterparts (e.g., EP patent numbers).
-
Continuation-in-part (CIP) applications that broaden the scope to include derivatives or expanded therapeutic uses.
Competitor Patents
Patents filed by companies such as Upjohn (now Pfizer), Roche, and Eli Lilly focus on similar benzodiazepine scaffolds but differ in substitution patterns, receptor selectivity, or chemical stability.
Patent Expiry and Freedom to Operate
-
The patent expiration date for U.S. Patent 4,855,294 is August 8, 2007, given a term extension for regulatory delays (patent term adjustments).
-
Post-expiration, generics or biosimilars can enter the market, subject to regulatory approval and freedom-to-operate assessments.
Implications for Development and Commercialization
-
The broad claims covering chemical scaffold and therapeutic use make this patent influential in the benzodiazepine class.
-
Subsequent patents have narrowed or expanded scope around specific derivatives, creating potential freedom-to-use challenges.
-
Aspirants seeking to develop competing anxiolytics must review this patent's claims for potentially overlapping chemical and therapeutic territory.
Key Takeaways
-
U.S. Patent 4,855,294 claims a class of benzodiazepine derivatives with specific structural features for use as sedatives and anxiolytics.
-
The patent's claims focus on chemical structure, synthesis methods, and therapeutic application, with a scope constrained by the specified substituents.
-
The patent landscape includes related patents with narrower claims or different derivatives, with expiration in 2007, after which generics can legally market similar compounds.
-
Developers should verify whether newer patents or recent regulatory exclusivities impact the freedom to operate in this chemical class.
FAQs
1. What is the main chemical class covered by U.S. Patent 4,855,294?
It covers benzodiazepine derivatives with specific substitutions aimed at receptor affinity enhancement.
2. How broad are the patent claims?
The claims encompass compounds with a core benzodiazepine structure and certain substituents, as well as synthesis methods and therapeutic uses, but exclude structures outside these parameters.
3. Is the patent still enforceable?
Its original expiration date was August 8, 2007. Extending patent term adjustments may have extended this slightly, but it is likely expired now.
4. What are the potential patent risks for developing similar compounds?
Post-expiration, products can enter the market freely. However, ongoing or newer patents related to specific derivatives, formulations, or uses may pose hurdles.
5. How does this patent influence the benzodiazepine market?
It forms foundational intellectual property for many subsequent derivatives; understanding its scope is critical for R&D and patent strategy.
References
[1] U.S. Patent 4,855,294. (1989). Benzodiazepine derivatives and methods of preparation. U.S. Patent and Trademark Office.
